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Abstract In eukaryotes, members of the Ero1 family control
oxidative protein folding in the endoplasmic reticulum (ER).
Yeast Ero1p is tightly associated with the ER membrane, despite
cleavage of the leader peptide, the only hydrophobic sequence
that could mediate lipid insertion. In contrast, human Ero1-LK
and a yeast mutant (Ero1pvC) lacking the 127 C-terminal amino
acids are soluble when expressed in yeast. Neither Ero1-LK nor
Ero1pvC complements an ERO1 disrupted strain. Appending the
yeast C-terminal tail to human Ero1-LK restores membrane
association and allows growth of ERO1 disrupted cells. There-
fore, the tail of Ero1p mediates membrane association and is
crucial for function. ß 2001 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
In Saccharomyces cerevisiae, the essential gene ERO1 en-
codes an endoplasmic reticulum (ER) resident oxidoreductin,
Ero1p, which plays a key role in the process of disul¢de bond
formation [1,2]. Ero1p has been shown to bind FAD [3], and
transfer oxidizing equivalents to protein disul¢de isomerase
(PDI) [4]. Its levels of expression correlate with tolerance to
exogenous reducing agents [1,2]. We found and characterized
two human homologues of ERO1, ERO1-LK and ERO1-LL
[5,6]. Also in human cells, PDI forms mixed disul¢des with
Ero1-LK [7] and Ero1-LL [8]. Altogether, the pathways of
disul¢de bond formation therefore seem conserved between
yeast and human cells, and electrons £ow from cargo proteins
to Ero1 proteins via PDI. Particularly in professional secre-
tory cells, Ero1 proteins must be continuously reoxidized so as
to sustain e⁄cient oxidative folding. However, the redox state
of the ER must be precisely controlled, as disul¢de bonds are
not only formed in this organelle, but also isomerized and
reduced before dislocation of misfolded proteins to the cytosol
for proteasomal degradation [9,10]. The precise mechanisms
that control the redox state of Ero1p are not fully understood.
Both human Ero1-LK and Ero1-LL complement a yeast
thermosensitive mutant strain (ero1-1) indicating functional
conservation amongst the Ero1 family. Indeed, the protein
sequences are rather conserved, especially around the
CXXCXXC motif, which is crucial for their function [1,5,7].
A striking sequence di¡erence, however, is represented by the
last C-terminal 127 residues of the yeast protein, which are
absent in the two human proteins. We have already demon-
strated that the presence of this C-terminal tail is not essential
for rescuing the thermosensitivity of ero1-1, as human Ero1-
LK and Ero1-LL and a truncated yeast mutant Ero1p-vC
lacking it allow growth at the restrictive temperature [5].
An intriguing feature of proteins of the Ero1 family is that,
despite the absence of hydrophobic sequences that could me-
diate lipid insertion, they fractionate with the membrane frac-
tion [1,5,6]. In this study, we provide evidence that Ero1p is
associated with the ER membrane even after cleavage of the
leader sequence. Biochemical and functional analyses exploit-
ing a ERO1 disrupted strain demonstrate that the C-terminal
tail mediates membrane association and is essential for Ero1p
function.
2. Materials and methods
2.1. Yeast strains and plasmids
The following S. cerevisiae strains were used: SEY6210: MATK ;
leu2-3, 112; ura3-52; his3-v200; trp1-v901; lys2-801; suc2-v9 ;
SEY6211: MATa; leu2-3, 112; ura3-52; his3-v200; trp1-v901;
ade2-101; suc2-v9 ; MPY201: MATK/MATa; leu2-3, 112/leu2-3,
112; ura3-52/ura3-52; his3-v200/his3-v200; trp1-v901/trp1-v901;
suc2-v9/suc2-v9; lys2-801/LYS2; ade2-101/ADE2; ERO1/
ERO1: :kanr ; MPY202: MATK ; leu2-3, 112; ura3-52; his3-v200;
trp1-v901; lys2-801; suc2-v9 ; ERO1: :kanr [pVT-ER01]; CKY559:
MATK ; leu2-3, 112; ura3-52; ero1-1.
These strains were grown and manipulated using standard tech-
niques [5,6]. Rich (YEP), minimal (SD) and sporulation media (SP)
were supplemented with 2% glucose or galactose (Difco Laboratories,
Detroit, MI, USA), as speci¢ed. The four genes of interest were
cloned into pVT102U, carrying the URA3 marker gene, and
YEP181, carrying LEU2, for constitutive and galactose inducible ex-
pression, respectively.
The chimeric gene ERO1-LK-CY was obtained by amplifying the C-
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terminal domain of the ERO1 gene using the primers CYfw:
GGGGTACCAACGGTTCTGAAAACAGG; CYrev: CGGGATC-
CCGTTAGCGGCCGCTACT, and cloning it in frame at the end
of the ERO1-LK gene, using the restriction sites KpnI and BamHI.
2.2. Construction of the ERO1: :kanr strain
To generate the ERO1: :kanr strain we used a one step gene re-
placement of ERO1 with a kanr cassette [11] generated by PCR using
the following primers, which contain 40 nucleotides from the £anking
sequences of the ERO1 gene and 19 or 21 nucleotides of the kanr




Three primers were designed to verify the ERO1 disruption: Kan1-
rev: CGA TAG ATT GTC GCA CC; ERO1verRev: GCA AGC
GCG GTT TAA GC; ERO1verFW: CCA CTT AAA CTG GTT
ATA.
Disruption was performed in the diploid strain MPY201. ERO1/
ERO1: :kanr strains were selected on YEP containing 200 Wg/ml Ge-
neticin (Gibco BRL, Milan, Italy). This strain was transformed with
pVTERO1, pVTERO1vC, and pVTERO1-LK and sporulated. The
ascus walls were partially digested with lyticase (Sigma, St. Louis,
MO, USA) and the spores individually distributed in a row on a
rich medium plate. The viability of the spore clones was then ana-
lyzed. One spore clone, ERO1: :kanr transformed with pVTERO1,
was selected (MPY202) and transformed with the four genes cloned
in the YEP181 plasmid (Fig. 1B).
Plasmid shu¥e was performed on SD supplemented with 2% galac-
tose, 50 mg/l uracil and 5P-£uoroorotic acid (5P-FOA; Sigma) to se-
lectively kill cells containing the pVTERO1, URA3 plasmid.
2.3. Membrane partitioning
The SEY6210 strain was transformed with pVTERO1myc, pVTER-
O1vC-HA, pVTERO1-LKmyc and pVTERO1-LK-CYmyc. The pres-
ence of C-terminal myc or HA tags did not alter the capability of the
recombinant proteins to rescue growth of the ero1-1 mutant at the
non-permissive temperature ([5], M. Pagani and S. Pilati, unpublished
results). Cells growing logarithmically at 30‡C were harvested, washed
and incubated in Tris^HCl 100 mM, pH 9.4, dithiothreitol (DTT) 10
mM for 10 min at room temperature. Cell were then incubated in 1.2
M sorbitol, 20 mM KPO4, pH 7.5 with 50 U lyticase for 45 min at
room temperature. After two washes with 1.2 M sorbitol, cells were
broken by freezing and thawing in 0.6 M sorbitol, 10 mM Tris^HCl
pH 7.4, plus a cocktail of protease inhibitors (Sigma). Samples were
centrifuged at 10 000Ug for 30 min to remove unbroken cells and
debris. The supernatant was further centrifuged at 100 000Ug for 45
min. The supernatant was transferred to a new tube and precipitated
with acetone. The pellet was either resuspended in sample bu¡er, or
resuspended in 0.6 M sorbitol, 10 mM Tris^HCl pH 7.4, plus protease
inhibitors supplemented with 1% Triton X-100 or 5 M urea and cen-
trifuged again. Samples were resolved by SDS^PAGE and analyzed
by Western blotting using monoclonal anti-myc (9E10) or anti-HA
(12CA5) antibodies. As controls, carboxypeptidase Y and PDI were
identi¢ed by Western blotting with antibodies kindly provided by Dr.
Karin Romisch (Cambridge, UK).
3. Results
3.1. The presence of the C-terminal tail is necessary for
complementation of ERO1 disrupted S. cerevisiae cells
We have previously shown that human Ero1-LK and Ero1-
LL allow the growth of a yeast thermosensitive mutant, ero1-1
at the restrictive temperature [5,6]. Also a yeast mutant lack-
ing the last 127 amino acids, Ero1pvC, was e¡ective, con¢rm-
ing that the C-terminal tail is not essential in this assay.
To gain insight into the molecular mechanisms underlying
complementation, we constructed an ERO1 disrupted yeast
strain by replacing the whole coding sequence with a kanr
marker gene [11] in a diploid strain (Fig. 1A). We transformed
heterozygous ERO1/ERO1: :kanr cells with plasmids driving
the expression of Ero1p, Ero1pvC or Ero1-LK (Fig. 1B).
Since ERO1 is an essential gene in yeast, only half of the
spores obtained by tetrad dissection assays are viable unless
the gene carried by the plasmid is able to complement. As
expected, all the spores derived from the ERO1 transformant
were viable. In contrast, only half of the spores derived from
the other two transformants were able to grow, namely those
carrying the chromosomal ERO1 (not shown). These data
indicate that mutants lacking the C-terminal tail were unable
to complement yeast cells devoid of endogenous Ero1p.
A plasmid shu¥e experiment was performed to determine
whether overexpression of Ero1-LK or Ero1pvC could sup-
press lethality of ERO1 disruption. For this purpose, we em-
ployed a strain in which the lethal chromosomal ERO1 dele-
tion is complemented by the yeast ERO1 gene on an episomal
URA3 marked plasmid. This strain does not grow on plates
Fig. 1. The presence of the C-terminal tail is essential to rescue an
ERO1 deleted strain. A: PCR was employed to con¢rm the replace-
ment of the ERO1 gene with the kanamycin resistance cassette in a
diploid strain (ERO1/ERO1: :kanr) and in the haploid strain
MPY202 derived after sporulation of the diploid. MPY202 is viable
due to an episomal ERO1 gene carried by an URA3 plasmid. B:
Schematic representation of the four genes introduced in the
MPY202 strain: S. cerevisiae ERO1, S. cerevisiae ERO1vC, human
ERO1-LK (both lacking the yeast C-terminal domain), and the chi-
meric human ERO1-LK to which the yeast C-tail was appended.
These genes were cloned into a LEU2 plasmid. C: Growth of di¡er-
ent transformants on medium containing 5P-FOA. Since the pres-
ence of an URA3 plasmid does not allow growth in the presence of
5P-FOA, only cells that had lost the episomal ERO1 gene carried by
an URA3 plasmid proliferate on media containing the drug. The
only viable MPY202 transformants are those carrying the S. cerevi-
siae ERO1 gene or the chimeric gene ERO1-LK-CY.
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containing 5-FOA because this compound is converted to a
toxic product by the URA3 gene product [12]. The ability of
high copy ERO1-LK or ERO1vC plasmids, LEU2 based, to
replace the URA3 marked plasmid bearing ERO1 was assayed
by growth on 5-FOA. As a positive control, a ERO1/LEU2
plasmid was tested. Unlike wild type ERO1, neither ERO1-LK
nor ERO1vC rescued ERO1: :kanr cells, con¢rming that the
C-terminal tail is essential for function. In agreement with
this, the chimera ERO1-LK-CY, in which the C-terminal tail
of the yeast gene is appended to human Ero1-LK, restored
viability of the ERO1 disrupted strain (Fig. 1C).
3.2. The leader sequence is cleaved from both yeast Ero1p and
human Ero1-LK
Apart from the N-terminal leader peptide, the sequence of
Ero1p does not contain hydrophobic stretches that could be
predicted to mediate transmembrane insertion. Nonetheless,
membrane partition experiments (Fig. 2A) con¢rmed that,
as previously reported [1], Ero1p was tightly associated with
membranes. A possible explanation for this would be that
Ero1p is a type II transmembrane protein, with an uncleaved
leader peptide. To ascertain whether this was the case, the
endogenous N-terminal hydrophobic sequence was replaced
by the invertase leader peptide, which is e⁄ciently recognized
by leader peptidase [13]. The resulting chimeric protein (SUC-
Ero1p) was also associated with membranes. Both Ero1p and
SUC-Ero1p could be partially extracted from the membrane
pellets by urea, con¢rming that they are not integral mem-
brane proteins. Mass spectrometry and N-terminal sequencing
con¢rmed that, as suggested by our previous fractionation
experiments [6], the leader sequence of human Ero1-LK is
e⁄ciently cleaved between residues G23 and E24.
3.3. The presence of the C-terminal tail is necessary to anchor
the protein to the membrane
Since the leader peptide is probably cleaved also from yeast
Ero1p, membrane association [1,5,6] could not re£ect inser-
tion in the lipid bilayers as type II proteins. We therefore
proceeded to further investigate the topological distribution
of the di¡erent mutants (Fig. 2A). Whilst the vast majority
of yeast Ero1p and SUC-Ero1p partitioned into the mem-
brane containing pellet, both Ero1-LK and Ero1pvC accumu-
lated in the soluble fraction, suggesting that the presence of
the tail was important for membrane association. In agree-
ment with this, the Ero1-LK-CY chimera accumulated in the
pellet, similarly to Ero1p. To further con¢rm its topological
role, we fused a myc-tagged version of the yeast C-tail to the
invertase leader peptide. Like Ero1p, the resulting chimeric
protein (SUC-CY) accumulated in the pellet and was in part
solubilized by urea. Ero1p, Ero1-LK-CY and SUC-CY were
solubilized by mild detergents, excluding the possibility that
their accumulation in the pellets was due to aggregation. Tak-
en together, these results indicated that Ero1p is a peripheral
membrane protein and its C-terminal domain plays an essen-
tial role in membrane association.
4. Discussion
In bacteria, disul¢de bonds are transferred from DsbB to
DsbA to cargo proteins in the periplasmic space. DsbB ulti-
mately donates electrons to the respiratory chain [14^16]. PDI
has been shown to complement DsbA null mutants [17,18],
although the two proteins are rather divergent in terms of
sequence. In eukaryotes and prokaryotes, therefore, Ero1p
and DsbB carry out similar functions, ensuring that their
main downstream partners, PDI and DsbA respectively, are
oxidized so as to transfer SS bonds to cargo proteins. None-
theless, while DsbB is a polytopic integral membrane protein
[19], Ero1p can be in part extracted from membranes in S.
cerevisiae by urea treatment, a characteristic of soluble or
peripheral membrane proteins. Moreover, also SUC-Ero1p,
which carries a cleaved leader sequence, fractionates in the
membrane containing pellet. Therefore, the endogenous
Ero1p signal sequence does not carry additional functions
apart from targeting to the ER. When expressed in human
cells, also Ero1-LK and Ero1-LL associated with the mem-
brane pellet, but could be solubilized following treatment at
pH 13 [6]. Cleavage of the leader sequences was con¢rmed by
mass spectrometry and N-terminal sequencing of Ero1-LK
puri¢ed from HeLa cells (A. Bachi, F. Talamo, B. Valsasina
and R. Sitia, unpublished observations).
Taken together, these ¢ndings indicate that neither Ero1p
nor Ero1-LK is inserted in the ER membrane. Their accumu-
lation in the membrane fractions could re£ect interactions
with integral membrane proteins.
Several lines of evidence point to a topological role for the
127 residue yeast tail. First, a deletion mutant lacking it
(Ero1pvC) no longer accumulates in the membrane pellet.
Interestingly, however, Ero1pvC is neither secreted nor local-
ized in the periplasmic space of yeast cells, implying that ER
Fig. 2. The C-terminal tail mediates the association of Ero1 proteins
with the ER membrane. A: After homogenization in the absence of
detergents, membrane associated (P) and soluble (S) proteins were
separated by centrifugation at 100 000Ug and resolved by SDS gel
electrophoresis under reducing conditions. Western blots were deco-
rated with 9E10 anti-myc antibodies. Pdi1p and CPY, two soluble
proteins localized in the ER lumen and in the vacuole respectively,
were used as controls and detected using speci¢c polyclonal antibod-
ies. B: Ero1 proteins which segregated with the membrane fraction
were treated with 5 M urea or 1% Triton X-100 for 30 min on ice,
centrifuged again at 100 000Ug and analyzed as in A.
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residency does not solely rely on membrane association. Sec-
ond, appending the yeast C-terminal tail to Ero1-LK is su⁄-
cient to cause membrane association of the human protein,
otherwise soluble when expressed in yeast cells. Finally, when
fused to the invertase leader sequence, a tagged version of the
yeast tail displayed a topology similar to Ero1p, indicating
that the 127 amino acids contained the information necessary
to mediate membrane association.
Membrane association correlates with the capability to
complement the growth of a yeast strain in which the endog-
enous gene has been disrupted (vERO1). Like Ero1pvC, hu-
man Ero1-LK expressed in yeast behaves as a soluble protein
and fails to complement vERO1 cells. This is somewhat un-
expected, as the majority of Ero1-LK accumulated in the
membrane fraction of human cells [6]. Therefore, the mecha-
nisms that mediate membrane association of Ero1 proteins
have diverged in yeast and mammalian cells. Appending the
127 residue yeast tail to human Ero1-LK restores membrane
association and allows complementation of vERO1 cells. It
will be of interest to identify proteins that speci¢cally interact
with the yeast tail, as these molecules may have a role in
controlling redox homeostasis within the ER.
Whilst unable to rescue the growth of the ERO1 disrupted
strain, both human Ero1-LK and yeast Ero1pvC complement
several phenotypic traits of the thermosensitive mutant ero1-1
[5,6]. Co-expressing SUC-CY and either Ero1pvC or Ero1-LK
was not su⁄cient to allow growth of vERO1 cells (data not
shown) indicating that physical continuity with the tail is nec-
essary for function. Taken together, these ¢ndings suggest
that in ero1-1 transformants, functional heterodimers are
formed in which the enzymatic activity is provided by the
tail-less transgenes (Ero1-LK or Ero1pvC), while the topolog-
ical information is contributed by the tail of the endogenous
Ero1p. These heterodimers, likely mediated by interactions
between the ‘heads’ of the molecules, do not appear to be
stable, since the vast majority of the tail-less proteins are
found in the soluble fraction also in ero1-1 cells. In all like-
lihood, a few active heterodimers are su⁄cient to ful¢l the
growth requirements of this mutant strain. Whilst allowing
growth at the non-permissive temperature, human Ero1-LK
and Ero1-LL restore other phenotypic traits of ero1-1, oxida-
tive folding of carboxypeptidase Y or DTT sensitivity, less
e⁄ciently than yeast Ero1p [5,6].
Since FAD is important for Ero1p function [3], mechanisms
must exist that allow its import into the ER lumen. The asso-
ciation of Ero1p with the ER membrane may be important
for FAD binding. However, Ero1p is active also in anaerobic
conditions [20], implying that electron acceptors other than
oxygen can be utilized. Electrons produced during the process
of disul¢de bond formation may be ultimately transported
into the cytosol. In view of the importance of tightly control-
ling the redox in this organelle, the observation that mem-
brane association is essential for function may re£ect topolog-
ical requirements for an e⁄cient and regulated (re)oxidation
of Ero1p.
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